Skip to main content
. 2022 Nov 30;1276:134690. doi: 10.1016/j.molstruc.2022.134690

Fig. 3.

Fig 3

The design strategy of the target (tetrahydro)thioquinazoline-N-arylacetamides XII and (tetrahydro)thioquinazoline-N-arylacetohydarzides XIII as anti-SARS-CoV-2 agents.